

The comparative evidence provided support the view that sickle cell disease is neglected compared with cystic fibrosis and haemophilia in relation to research and funding in the UK. The highest value for each indicator, often observed for cystic fibrosis, provides a benchmark target for the other two conditions. More dedicated research funding would likely have a ripple effect on other indicators, which could guide public health policies and have a major effect on the quality of life of people living with sickle cell disease.
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet